Johnson & Johnson Reports 2013 Third-Quarter Results:

Sales of $17.6 Billion increased 3.1% Versus 2012 Third Quarter;

Third-Quarter EPS was $1.04

Excluding Special Items, 2013 Third-Quarter EPS of $1.36 increased 8.8%*

15 Oct, 2013, 07:45 ET from Johnson & Johnson

NEW BRUNSWICK, N.J., Oct. 15, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.6 billion for the third quarter of 2013, an increase of 3.1% as compared to the third quarter of 2012. Operational results increased 4.7% and the negative impact of currency was 1.6%. Domestic sales increased 1.7%.  International sales increased 4.2%, reflecting operational growth of 7.1% and a negative currency impact of 2.9%.

Net earnings ** and diluted earnings per share for the third quarter of 2013 were $3.0 billion and $1.04, respectively. The third quarter results included after-tax special items of approximately $0.9 billion, primarily related to an increase in the accrual for litigation expenses, in-process research and development expense, and integration and transaction costs related to the acquisition of Synthes, Inc.  Third quarter 2012 net earnings included after-tax special items of approximately $0.6 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were $3.9 billion and diluted earnings per share were $1.36, representing increases of 11.3% and 8.8%, respectively, as compared to the same period in 2012.*  

"Our third-quarter results reflect the solid, demonstrable results in achieving our near-term priorities while also advancing our longer term strategic growth drivers," said Alex Gorsky, Chairman and Chief Executive Officer. "Our key products and successful new product launches delivered strong growth. We continue to progress our pipelines with a number of regulatory approvals, the submission of new drug applications, and execution of strategic collaborations. Our investments further strengthen our ability to deliver sustainable growth and bring meaningful innovations to patients and consumers."

The Company increased its earnings guidance for full-year 2013 to $5.44 - $5.49 per share. The Company's guidance excludes the impact of special items.

Worldwide Consumer sales of $3.6 billion for the third quarter represented an increase of 0.8% versus the prior year consisting of an operational increase of 2.0% and a negative impact from currency of 1.2%.  Domestic sales increased 0.9%. International sales increased 0.8%, which reflected an operational increase of 2.6% and a negative currency impact of 1.8%.

Positive contributors to operational results were U.S. sales of TYLENOL® and MOTRIN® analgesics; upper respiratory over the counter medicines; AVEENO® skin care products and international baby care products.

Worldwide Pharmaceutical sales of $7.0 billion for the third quarter represented an increase of 9.9% versus the prior year with operational growth of 10.9% and a negative impact from currency of 1.0%.  Domestic sales increased 7.9%. International sales increased 12.0% which reflected an operational increase of 14.0% and a negative currency impact of 2.0%. 

Primary contributors to operational sales growth were INVEGA®  SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; REMICADE® (infliximab) and SIMPONI® (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; VELCADE® (bortezomib), a treatment for multiple myeloma; PREZISTA® (darunavir), a treatment for HIV; and sales of new products.

The strong sales results of new products include ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; XARELTO® (rivaroxaban), an oral anticoagulant; and INVOKANA® (canagliflozin) for the treatment of adults with type 2 diabetes.

During the quarter, the European Commission approved SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who had an inadequate response to conventional therapy. In addition, the European Commission approved the use of VELCADE® (bortezomib) as induction therapy in combination with dexamethasone or thalidomide and dexamethasone and applies to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with hematological stem cell transplantation.

Also, during the quarter, the European Commission approved STELARA® (ustekinumab), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug therapy has been inadequate, and the U.S. Food and Drug Administration (FDA) approved STELARA®  alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. Additionally, the FDA approved SIMPONI® ARIA™ (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

In September, the Committee for Medical Products for Human Use of The European Medicines Agency granted a positive opinion recommending approval of INVOKANA® (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycemic control. 

In October, we announced the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc. We acquired all rights to develop and commercialize GSK2336805, including in combination with other drugs.

Worldwide Medical Devices and Diagnostics sales of $6.9 billion for the third quarter represented a decrease of 2.0% versus the prior year consisting of an operational increase of 0.3% and a negative currency impact of 2.3%. Domestic sales decreased 4.2%. International sales decreased 0.1%, which reflected an operational increase of 4.2% and a negative currency impact of 4.3%.

Primary contributors to operational growth were sales from Biosense Webster's electrophysiology products in the Cardiovascular Care business; joint reconstruction products in the Orthopaedics business; international sales in the Surgical Care business; and biosurgical and international sales of energy products in the Specialty Surgery business.

About Johnson & Johnson Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,700 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings ** and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

** Net earnings attributable to Johnson & Johnson.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development can be found on the Company's website at www.investor.jnj.com.

NOTE TO INVESTORS (This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; the effects of a continued federal government shutdown including the FDA's ability to take new regulatory submissions and continue review of our existing submissions without delays; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

THIRD QUARTER

NINE MONTHS

Percent Change

Percent Change

2013

2012

Total

Operations

Currency

2013

2012

Total

Operations

Currency

Sales to customers by

segment of business

Consumer

  U.S.

$

1,225

1,214

0.9

%

0.9

-

$

3,899

3,843

1.5

%

1.5

-

    International

2,386

2,367

0.8

2.6

(1.8)

7,045

6,952

1.3

2.7

(1.4)

3,611

3,581

0.8

2.0

(1.2)

10,944

10,795

1.4

2.3

(0.9)

Pharmaceutical

    U.S.

3,549

3,288

7.9

7.9

-

10,397

9,408

10.5

10.5

-

    International

3,487

3,114

12.0

14.0

(2.0)

10,432

9,418

10.8

12.9

(2.1)

7,036

6,402

9.9

10.9

(1.0)

20,829

18,826

10.6

11.7

(1.1)

Med Devices & Diagnostics

    U.S.

3,151

3,289

(4.2)

(4.2)

-

9,600

9,119

5.3

5.3

-

    International

3,777

3,780

(0.1)

4.2

(4.3)

11,584

10,926

6.0

10.0

(4.0)

6,928

7,069

(2.0)

0.3

(2.3)

21,184

20,045

5.7

7.9

(2.2)

U.S.

7,925

7,791

1.7

1.7

-

23,896

22,370

6.8

6.8

-

International

9,650

9,261

4.2

7.1

(2.9)

29,061

27,296

6.5

9.2

(2.7)

Worldwide

$

17,575

17,052

3.1

%

4.7

(1.6)

$

52,957

49,666

6.6

%

8.1

(1.5)

 

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

THIRD QUARTER

NINE MONTHS

Percent Change

Percent Change

2013

2012

Total

Operations

Currency

2013

2012

Total

Operations

Currency

Sales to customers by

geographic area

U.S.

$

7,925

7,791

1.7

%

1.7

-

$

23,896

22,370

6.8

%

6.8

-

Europe

4,478

3,983

12.4

8.4

4.0

13,631

12,342

10.4

8.6

1.8

Western Hemisphere excluding U.S.

1,842

1,824

1.0

8.0

(7.0)

5,530

5,266

5.0

10.3

(5.3)

Asia-Pacific, Africa

3,330

3,454

(3.6)

5.1

(8.7)

9,900

9,688

2.2

9.2

(7.0)

International

9,650

9,261

4.2

7.1

(2.9)

29,061

27,296

6.5

9.2

(2.7)

Worldwide

$

17,575

$17,052

3.1

%

4.7

(1.6)

$

52,957

$49,666

6.6

%

8.1

(1.5)

 

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings 

(Unaudited; in Millions Except Per Share Figures)

THIRD QUARTER

2013

2012

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)

Sales to customers

$

17,575

100.0

$

17,052

100.0

3.1

Cost of products sold

5,344

30.4

5,597

32.8

(4.5)

Selling, marketing and administrative expenses

5,314

30.2

5,228

30.6

1.6

Research and development expense

2,042

11.6

1,923

11.3

6.2

In-process research and development

178

1.0

679

4.0

Interest (income) expense, net

87

0.5

120

0.7

Other (income) expense, net

943

5.4

(90)

(0.5)

Earnings before provision for taxes on income

3,667

20.9

3,595

21.1

2.0

Provision for taxes on income

685

3.9

966

5.7

(29.1)

Net earnings

2,982

17.0

2,629

15.4

13.4

Add: Net loss attributable to noncontrolling interest

-

-

339

2.0

Net earnings attributable to Johnson & Johnson

$

2,982

17.0

$

2,968

17.4

0.5

Net earnings per share attributable to Johnson & Johnson (Diluted)

$

1.04

1.05

(1.0)

Average shares outstanding (Diluted)

2,881.2

2,818.1

Effective tax rate

18.7

%

26.9

%

Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)

Earnings before provision for taxes on income

$

4,831

27.5

$

4,525

26.5

6.8

Net earnings attributable to Johnson & Johnson

$

3,919

22.3

$

3,521

20.6

11.3

Net earnings per share attributable to Johnson & Johnson (Diluted)

$

1.36

$

1.25

8.8

Effective tax rate

18.9

%

22.2

%

(1) See Reconciliation of Non-GAAP Financial Measures.

 

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

NINE MONTHS

2013

2012

Percent

Percent to

Percent to

Increase

Amount

Sales

Amount

Sales

(Decrease)

Sales to customers

$

52,957

100.0

$

49,666

100.0

6.6

Cost of products sold

16,387

30.9

15,655

31.5

4.7

Selling, marketing and administrative expenses

15,913

30.0

15,208

30.6

4.6

Research and development expense

5,772

10.9

5,334

10.7

8.2

In-process research and development

242

0.5

1,108

2.2

Interest (income) expense, net

292

0.6

379

0.8

Other (income) expense, net

1,630

3.1

1,307

2.7

Earnings before provision for taxes on income

12,721

24.0

10,675

21.5

19.2

Provision for taxes on income

2,409

4.5

2,728

5.5

(11.7)

Net earnings

10,312

19.5

7,947

16.0

29.8

Add: Net loss attributable to noncontrolling interest

-

-

339

0.7

Net earnings attributable to Johnson & Johnson

$

10,312

19.5

$

8,286

16.7

24.5

Net earnings per share attributable to Johnson & Johnson (Diluted)

$

3.58

$

2.96

20.9

Average shares outstanding (Diluted)

2,879.0

2,805.0

Effective tax rate

18.9

%

25.6

%

Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)

Earnings before provision for taxes on income

$

15,260

28.8

$

14,099

28.4

8.2

Net earnings attributable to Johnson & Johnson

$

12,315

23.3

$

10,969

22.1

12.3

Net earnings per share attributable to Johnson & Johnson (Diluted)

$

4.28

$

3.91

9.5

Effective tax rate

19.3

%

22.2

%

(1) See Reconciliation of Non-GAAP Financial Measures.

 

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measures

Third Quarter

% Incr. /

Nine Months YTD

% Incr. /

(Dollars in Millions Except Per Share Data)

2013

2012

(Decr.)

2013

2012

(Decr.)

Earnings before provision for taxes on income - as reported

$

3,667

3,595

2.0

%

$

12,721

$

10,675

19.2

%

Litigation expenses

872

89

1,776

758

In-process research and development

178

679

242

1,108

Synthes integration/transaction costs and currency related

122

165

(1)

502

622

DePuy ASR™Hip program

35

27

117

27

Intangible asset write-downs

-

-

-

939

Other

(43)

(30)

(98)

(30)

Earnings before provision for taxes on income - as adjusted

$

4,831

4,525

6.8

%

$

15,260

14,099

8.2

%

Net Earnings attributable to Johnson & Johnson - as reported

$

2,982

2,968

0.5

%

$

10,312

8,286

24.5

%

Litigation expenses

720

70

1,419

681

In-process research and development

126

340

(2)

168

684

Synthes integration/transaction costs and currency related

103

135

373

593

DePuy ASR™ Hip program

31

24

122

24

Intangible asset write-downs

-

-

-

717

Other

(43)

(16)

(79)

(16)

Net Earnings attributable to Johnson & Johnson - as adjusted 

$

3,919

3,521

11.3

%

$

12,315

10,969

12.3

%

Diluted Net Earnings per share attributable to Johnson & Johnson - as reported

$

1.04

1.05

(1.0)

%

$

3.58

2.96

20.9

%

Litigation expenses

0.25

0.02

0.49

0.24

In-process research and development

0.04

0.13

0.06

0.24

Synthes integration/transaction costs and currency related

0.04

0.05

0.13

0.21

DePuy ASR™ Hip program

0.01

0.01

0.04

0.01

Intangible asset write-downs

-

-

-

0.26

Other

(0.02)

(0.01)

(0.02)

(0.01)

Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted 

$

1.36

1.25

8.8

%

$

4.28

3.91

9.5

%

(1) Represents inventory step-up recorded in cost of products sold

(2) In-process research and development of $679M offset by $339M reported as net loss attributable to noncontrolling interest

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

THIRD QUARTER

NINE MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational(1)

Currency

CONSUMER SEGMENT (2) (4)

BABY CARE

US

$

99

104

-4.8%

-4.8%

-

$

308

309

-0.3%

-0.3%

-

Intl

461

460

0.2%

4.3%

-4.1%

1,402

1,373

2.1%

5.2%

-3.1%

WW

560

564

-0.7%

2.6%

-3.3%

1,710

1,682

1.7%

4.2%

-2.5%

ORAL CARE

US

142

162

-12.3%

-12.3%

-

449

476

-5.7%

-5.7%

-

Intl

253

251

0.8%

3.2%

-2.4%

755

732

3.1%

4.8%

-1.7%

WW

395

413

-4.4%

-3.0%

-1.4%

1,204

1,208

-0.3%

0.8%

-1.1%

OTC (3)

US

310

263

17.9%

17.9%

-

954

801

19.1%

19.1%

-

Intl

665

653

1.8%

2.0%

-0.2%

1,995

1,949

2.4%

2.7%

-0.3%

WW

975

916

6.4%

6.5%

-0.1%

2,949

2,750

7.2%

7.4%

-0.2%

SKIN CARE

US

404

390

3.6%

3.6%

-

1,320

1,314

0.5%

0.5%

-

Intl

520

514

1.2%

2.1%

-0.9%

1,414

1,410

0.3%

0.9%

-0.6%

WW

924

904

2.2%

2.7%

-0.5%

2,734

2,724

0.4%

0.7%

-0.3%

WOMEN'S HEALTH

US

77

81

-4.9%

-4.9%

-

242

254

-4.7%

-4.7%

-

Intl

331

326

1.5%

4.3%

-2.8%

978

964

1.5%

4.2%

-2.7%

WW

408

407

0.2%

2.5%

-2.3%

1,220

1,218

0.2%

2.4%

-2.2%

WOUND CARE/OTHER (3)

US

193

214

-9.8%

-9.8%

-

626

689

-9.1%

-9.1%

-

Intl

156

163

-4.3%

-3.0%

-1.3%

501

524

-4.4%

-3.8%

-0.6%

WW

349

377

-7.4%

-6.9%

-0.5%

1,127

1,213

-7.1%

-6.8%

-0.3%

TOTAL CONSUMER

US

1,225

1,214

0.9%

0.9%

-

3,899

3,843

1.5%

1.5%

-

Intl

2,386

2,367

0.8%

2.6%

-1.8%

7,045

6,952

1.3%

2.7%

-1.4%

WW

$

3,611

3,581

0.8%

2.0%

-1.2%

$

10,944

10,795

1.4%

2.3%

-0.9%

 

See footnotes at end of schedule

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

THIRD QUARTER

NINE MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2) (4)

IMMUNOLOGY

US

$

1,648

1,600

3.0%

3.0%

-

$

4,865

4,524

7.5%

7.5%

-

Intl

695

484

43.6%

47.7%

-4.1%

1,923

1,374

40.0%

43.3%

-3.3%

WW

2,343

2,084

12.4%

13.4%

-1.0%

6,788

5,898

15.1%

15.9%

-0.8%

REMICADE

US 

1,013

940

7.8%

7.8%

-

2,909

2,712

7.3%

7.3%

-

US Exports (5)

291

379

-23.2%

-23.2%

-

972

1,123

-13.4%

-13.4%

-

Intl

385

272

41.5%

46.1%

-4.6%

1,080

800

35.0%

38.2%

-3.2%

WW

1,689

1,591

6.2%

7.0%

-0.8%

4,961

4,635

7.0%

7.5%

-0.5%

SIMPONI

US

111

93

19.4%

19.4%

-

292

220

32.7%

32.7%

-

Intl

155

92

68.5%

74.9%

-6.4%

386

206

87.4%

95.3%

-7.9%

WW

266

185

43.8%

47.0%

-3.2%

678

426

59.2%

63.0%

-3.8%

STELARA

US

233

188

23.9%

23.9%

-

692

469

47.5%

47.5%

-

Intl

137

99

38.4%

38.6%

-0.2%

395

287

37.6%

38.5%

-0.9%

WW

370

287

28.9%

29.0%

-0.1%

1,087

756

43.8%

44.1%

-0.3%

OTHER IMMUNOLOGY

US

-

-

-

-

-

-

-

-

-

-

Intl

18

21

-14.3%

-8.1%

-6.2%

62

81

-23.5%

-21.4%

-2.1%

WW

18

21

-14.3%

-8.1%

-6.2%

62

81

-23.5%

-21.4%

-2.1%

INFECTIOUS DISEASES

US

278

259

7.3%

7.3%

-

775

738

5.0%

5.0%

-

Intl

543

536

1.3%

-0.1%

1.4%

1,831

1,600

14.4%

14.7%

-0.3%

WW

821

795

3.3%

2.4%

0.9%

2,606

2,338

11.5%

11.7%

-0.2%

INCIVO

US

-

-

-

-

-

-

-

-

-

-

Intl

76

71

7.0%

5.3%

1.7%

410

305

34.4%

36.1%

-1.7%

WW

76

71

7.0%

5.3%

1.7%

410

305

34.4%

36.1%

-1.7%

INTELENCE

US

47

45

4.4%

4.4%

-

138

130

6.2%

6.2%

-

Intl

45

49

-8.2%

-9.2%

1.0%

146

135

8.1%

8.1%

0.0%

WW

92

94

-2.1%

-2.6%

0.5%

284

265

7.2%

7.2%

0.0%

PREZISTA

US

215

181

18.8%

18.8%

-

578

507

14.0%

14.0%

-

Intl

195

183

6.6%

4.4%

2.2%

634

554

14.4%

14.0%

0.4%

WW

410

364

12.6%

11.5%

1.1%

1,212

1,061

14.2%

14.0%

0.2%

OTHER INFECTIOUS DISEASES

US

16

33

-51.5%

-51.5%

-

59

101

-41.6%

-41.6%

-

Intl

227

233

-2.6%

-3.4%

0.8%

641

606

5.8%

6.0%

-0.2%

WW

243

266

-8.6%

-9.3%

0.7%

700

707

-1.0%

-0.8%

-0.2%

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

THIRD QUARTER

NINE MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

NEUROSCIENCE

US

601

678

-11.4%

-11.4%

-

1,973

2,010

-1.8%

-1.8%

-

Intl

991

990

0.1%

4.6%

-4.5%

3,043

3,019

0.8%

4.6%

-3.8%

WW

1,592

1,668

-4.6%

-1.9%

-2.7%

5,016

5,029

-0.3%

2.0%

-2.3%

CONCERTA/METHYLPHENIDATE

US

38

150

-74.7%

-74.7%

-

262

493

-46.9%

-46.9%

-

Intl

104

104

0.0%

3.5%

-3.5%

351

337

4.2%

6.6%

-2.4%

WW

142

254

-44.1%

-42.7%

-1.4%

613

830

-26.1%

-25.1%

-1.0%

INVEGA

US

82

78

5.1%

5.1%

-

229

223

2.7%

2.7%

-

Intl

65

62

4.8%

11.0%

-6.2%

200

180

11.1%

16.9%

-5.8%

WW

147

140

5.0%

7.8%

-2.8%

429

403

6.5%

9.1%

-2.6%

INVEGA SUSTENNA/ XEPLION

US

180

130

38.5%

38.5%

-

502

350

43.4%

43.4%

-

Intl

144

82

75.6%

72.9%

2.7%

396

218

81.7%

80.1%

1.6%

WW

324

212

52.8%

51.7%

1.1%

898

568

58.1%

57.5%

0.6%

RISPERDAL CONSTA

US

114

113

0.9%

0.9%

-

327

336

-2.7%

-2.7%

-

Intl

212

238

-10.9%

-8.7%

-2.2%

670

731

-8.3%

-6.1%

-2.2%

WW

326

351

-7.1%

-5.6%

-1.5%

997

1,067

-6.6%

-5.1%

-1.5%

OTHER NEUROSCIENCE

US

187

207

-9.7%

-9.7%

-

653

608

7.4%

7.4%

-

Intl

466

504

-7.5%

-0.7%

-6.8%

1,426

1,553

-8.2%

-2.8%

-5.4%

WW

653

711

-8.2%

-3.4%

-4.8%

2,079

2,161

-3.8%

0.1%

-3.9%

ONCOLOGY

US

227

145

56.6%

56.6%

-

632

371

70.4%

70.4%

-

Intl

754

483

56.1%

57.1%

-1.0%

2,028

1,439

40.9%

42.9%

-2.0%

WW

981

628

56.2%

57.0%

-0.8%

2,660

1,810

47.0%

48.6%

-1.6%

VELCADE

US

-

-

-

-

-

-

-

-

-

-

Intl

404

327

23.5%

26.3%

-2.8%

1,136

998

13.8%

16.7%

-2.9%

WW

404

327

23.5%

26.3%

-2.8%

1,136

998

13.8%

16.7%

-2.9%

ZYTIGA

US

204

136

50.0%

50.0%

-

539

349

54.4%

54.4%

-

Intl

260

129

*

97.1%

4.5%

664

348

90.8%

89.1%

1.7%

WW

464

265

75.1%

72.9%

2.2%

1,203

697

72.6%

71.7%

0.9%

OTHER ONCOLOGY

US

23

9

*

*

-

93

22

*

*

-

Intl

90

27

*

*

-5.2%

228

93

*

*

-5.7%

WW

113

36

*

*

-3.8%

321

115

*

*

-4.6%

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

THIRD QUARTER

NINE MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

TOTAL OTHER

US

795

606

31.2%

31.2%

-

2,152

1,765

21.9%

21.9%

-

Intl

504

621

-18.8%

-18.8%

0.0%

1,607

1,986

-19.1%

-18.7%

-0.4%

WW

1,299

1,227

5.9%

5.9%

0.0%

3,759

3,751

0.2%

0.4%

-0.2%

ACIPHEX/PARIET

US

89

80

11.3%

11.3%

-

289

280

3.2%

3.2%

-

Intl

44

115

-61.7%

-62.0%

0.3%

152

369

-58.8%

-58.7%

-0.1%

WW

133

195

-31.8%

-32.0%

0.2%

441

649

-32.0%

-32.0%

0.0%

PROCRIT/EPREX

US

204

198

3.0%

3.0%

-

627

634

-1.1%

-1.1%

-

Intl

140

161

-13.0%

-14.4%

1.4%

430

502

-14.3%

-14.9%

0.6%

WW

344

359

-4.2%

-4.8%

0.6%

1,057

1,136

-7.0%

-7.3%

0.3%

XARELTO

US

246

68

*

*

-

593

144

*

*

-

Intl

-

-

-

-

-

-

-

-

-

-

WW

246

68

*

*

-

593

144

*

*

-

OTHER

US

256

260

-1.5%

-1.5%

-

643

707

-9.1%

-9.1%

-

Intl

320

345

-7.2%

-6.4%

-0.8%

1,025

1,115

-8.1%

-7.2%

-0.9%

WW

576

605

-4.8%

-4.4%

-0.4%

1,668

1,822

-8.5%

-7.9%

-0.6%

TOTAL PHARMACEUTICAL

US

3,549

3,288

7.9%

7.9%

-

10,397

9,408

10.5%

10.5%

-

Intl

3,487

3,114

12.0%

14.0%

-2.0%

10,432

9,418

10.8%

12.9%

-2.1%

WW

$

7,036

6,402

9.9%

10.9%

-1.0%

$

20,829

18,826

10.6%

11.7%

-1.1%

See footnotes at end of schedule

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

THIRD QUARTER

NINE MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

MEDICAL DEVICES AND DIAGNOSTICS (2)

CARDIOVASCULAR CARE

US

$

196

195

0.5%

0.5%

-

$

598

566

5.7%

5.7%

-

Intl

305

298

2.3%

6.6%

-4.3%

945

913

3.5%

7.5%

-4.0%

WW

501

493

1.6%

4.2%

-2.6%

1,543

1,479

4.3%

6.8%

-2.5%

DIABETES CARE

US

237

328

-27.7%

-27.7%

-

779

1,017

-23.4%

-23.4%

-

Intl

320

301

6.3%

6.5%

-0.2%

967

955

1.3%

2.2%

-0.9%

WW

557

629

-11.4%

-11.3%

-0.1%

1,746

1,972

-11.5%

-11.0%

-0.5%

DIAGNOSTICS

US

222

256

-13.3%

-13.3%

-

711

767

-7.3%

-7.3%

-

Intl

237

257

-7.8%

-2.8%

-5.0%

708

772

-8.3%

-4.1%

-4.2%

WW

459

513

-10.5%

-8.0%

-2.5%

1,419

1,539

-7.8%

-5.7%

-2.1%

INFECTION PREVENTION/OTHER

US

91

98

-7.1%

-7.1%

-

271

313

-13.4%

-13.4%

-

Intl

129

134

-3.7%

4.3%

-8.0%

395

393

0.5%

6.9%

-6.4%

WW

220

232

-5.2%

-0.5%

-4.7%

666

706

-5.7%

-2.1%

-3.6%

ORTHOPAEDICS

US 

1,232

1,242

-0.8%

-0.8%

-

3,767

2,898

30.0%

30.0%

-

Intl

1,051

1,048

0.3%

3.4%

-3.1%

3,286

2,513

30.8%

34.3%

-3.5%

WW

2,283

2,290

-0.3%

1.1%

-1.4%

7,053

5,411

30.3%

31.9%

-1.6%

SPECIALTY SURGERY

US

321

308

4.2%

4.2%

-

971

971

0.0%

0.0%

-

Intl

305

289

5.5%

9.2%

-3.7%

938

900

4.2%

7.2%

-3.0%

WW

626

597

4.9%

6.7%

-1.8%

1,909

1,871

2.0%

3.4%

-1.4%

SURGICAL CARE 

US

587

602

-2.5%

-2.5%

-

1,695

1,797

-5.7%

-5.7%

-

Intl

947

949

-0.2%

3.9%

-4.1%

2,935

3,019

-2.8%

0.6%

-3.4%

WW

1,534

1,551

-1.1%

1.4%

-2.5%

4,630

4,816

-3.9%

-1.8%

-2.1%

VISION CARE

US

265

260

1.9%

1.9%

-

808

790

2.3%

2.3%

-

Intl

483

504

-4.2%

4.9%

-9.1%

1,410

1,461

-3.5%

4.3%

-7.8%

WW

748

764

-2.1%

3.9%

-6.0%

2,218

2,251

-1.5%

3.6%

-5.1%

TOTAL MEDICAL DEVICES AND DIAGNOSTICS

US

3,151

3,289

-4.2%

-4.2%

-

9,600

9,119

5.3%

5.3%

-

Intl

3,777

3,780

-0.1%

4.2%

-4.3%

11,584

10,926

6.0%

10.0%

-4.0%

WW

$

6,928

7,069

-2.0%

0.3%

-2.3%

$

21,184

20,045

5.7%

7.9%

-2.2%

* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Nutritionals now reflected in Wound Care/Other, previously reported in OTC/Nutritionals

(4) Prior year amounts have been reclassified to conform to current year product disclosure

(5) Reported as U.S. sales

SOURCE Johnson & Johnson



RELATED LINKS

http://www.jnj.com